Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Howard Sandler MD, MS, FASTRO

Howard M. Sandler MD, MS, FASTRO

Ronald H. Bloom Family Chair in Cancer Therapeutics and Professor and Chairman of Radiation Oncology, Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California

Dr. Sandler is the Ronald H. Bloom Family Chair in Cancer Therapeutics and Professor and Chairman of Radiation Oncology at the Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles.  He received his undergraduate degree, masters in Physics and medical degree from the University of Connecticut and completed his training in Radiation Oncology at the University of Pennsylvania.  He was recruited to Cedars-Sinai in 2008 from the University of Michigan’s National Cancer Institute-designated Comprehensive Cancer Center, where he served as Newman Family Professor of Radiation Oncology.

Dr. Sandler’s research interests include prostate and other genitourinary tumors, as well as a broad range of subjects related to radiation oncology. He has received a number of grants from the National Institutes of Health and other major agencies to conduct research in these areas, and is a leader in developing technology that allows radiation beams to target prostate cancer tumors with greater accuracy and fewer side effects. As chairman of the Radiation Therapy Oncology Group -- now part of NRG Oncology -- Genitourinary Cancer Committee since 1997, he’s led or shaped a number of practice-changing national clinical trials. He has written more than 250 peer-reviewed publications primarily on prostate cancer and radiation therapy.